摘要
目的:观察岩舒注射液联合放化疗治疗不可手术Ⅲ期NSCLC的疗效及副反应。方法:将90例晚期不可手术Ⅲ期NSCLC患者随机分为综合治疗组和对照治疗组(各45例),按照NCCN2004NSCLC治疗指南进行治疗,综合治疗组加用岩舒注射液20ml/d,与放化疗同步进行。结果:对照治疗组血浆CD4+、CD4+/CD8+比值较综合治疗组明显降低(P<0.05),对照治疗组、综合治疗组的RR分别是51.1%、57.8%(P>0.05),DCR分别是77.8%、93.3%(P<0.05)。综合治疗组中常见副反应发生率较对照治疗组明显降低(P<0.05)。结论:岩舒注射液能提高不可手术Ⅲ期NSCLC的临床疗效,降低放化疗的副反应。
Objective：To evaluate the efficacy of yan - shu Injection combined with chemoradiotherapy in unre- sectable stage Ⅲ non small cell lung cancer （NSCLC） patients. Methods： Ninety patients with unresectable stage II1 non small cell lung cancer patients were randomized into comprehensive treatment group and control treatment group ：All patients received standard treatment according to the NCCN 2004 cancer practice guidelines and Yan -shu injection was added to the comprehensive treatment group. Results ：The CD4 ＋ ,CD4 ＋/CD8 ＋of patients in the control treatment group were all significantly decreased compared to the comprehensive treatment group （P 〈 0.05 ）, the RR of control treatment group and comprehensive treatment group were 51.1% ,57.8% （ P 〉 0.05 ） ,while DCR（ disease control rate）were 77.8% ,93.3 % （P 〈 0.05 ）respectively, and the adverse events of comprehensive treatment group was significantly decreased compared to the control treatment group （ P 〈 0.05 ）. Conclusion ： The Yanshu injection can improve the efficacy of unresectable stage Ⅲ NSCLC and decrease adverse events from chemoradiotherapy.
出处
《现代肿瘤医学》
CAS
2008年第8期1320-1322,共3页
Journal of Modern Oncology
